Literature DB >> 9651008

Expression of differential immune factors in temporal cortex and cerebellum: the role of alpha-1-antichymotrypsin, apolipoprotein E, and reactive glia in the progression of Alzheimer's disease.

S D Styren1, M I Kamboh, S T DeKosky.   

Abstract

A variety of factors and processes have been implicated in the development and progression of the pathology of Alzheimer's Disease (AD), including amyloid fragment deposition, reactive gliosis, alpha-1-antichymotrypsin (ACT), and apolipoprotein E (APOE). Carriers of the APOE 4 allele have been shown to have an enhanced risk of developing AD, and the ACT signal peptide A/A genotype may modify the APOEepsilon4 risk. The protein products of these genes have been shown to enhance conversion of diffuse beta amyloid (Abeta) fibrils, which are found in diffuse plaques, to the fibrillar form found in neuritic plaques. In affected regions of AD brain, ACT and APOE colocalize with Abeta deposits and reactive microglia and astrocytes. We examined the regional distribution of ACT, APOE, and reactive glia in temporal cortex, where neuritic plaques are abundant, and cerebellum (in areas where diffuse plaques but not neuritic plaques accumulate) to examine the relationship of these markers to the deposition of Abeta. In temporal cortex, ACT and APOE staining was localized to plaque-like profiles, reactive astrocytes, and blood vessels; human leukocyte antigen-DR (HLA-DR) and glial fibrillary acidic protein (GFAP) staining revealed focal clusters of reactive microglia and astrocytes. In cerebellum, ACT and APOE immunoreactivity was never localized to plaque-like profiles but was weakly localized to unreactive astrocytes; weak HLA-DR and GFAP immunoreactivity was present on quiescent microglia throughout the cerebellum. The lack of fibrillar amyloid deposits in cerebellum, despite the presence of well-characterized markers thought to mediate the production of Abeta, suggests that this brain region may be lacking certain factors necessary for fibril formation or that the cerebellum responds differently to stimuli that successfully mediate inflammation in affected cortex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9651008

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  11 in total

1.  Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.

Authors:  Burcu Zeydan; Val J Lowe; Christopher G Schwarz; Scott A Przybelski; Nirubol Tosakulwong; Samantha M Zuk; Matthew L Senjem; Jeffrey L Gunter; Rosebud O Roberts; Michelle M Mielke; Eduardo E Benarroch; Moses Rodriguez; Mary M Machulda; Timothy G Lesnick; David S Knopman; Ronald C Petersen; Clifford R Jack; Kejal Kantarci; Orhun H Kantarci
Journal:  Mult Scler       Date:  2017-05-05       Impact factor: 6.312

2.  Expression of glia maturation factor in neuropathological lesions of Alzheimer's disease.

Authors:  R Thangavel; D Stolmeier; X Yang; P Anantharam; A Zaheer
Journal:  Neuropathol Appl Neurobiol       Date:  2012-10       Impact factor: 8.090

3.  Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice.

Authors:  Joo-Yong Lee; Toby B Cole; Richard D Palmiter; Sang Won Suh; Jae-Young Koh
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

4.  Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.

Authors:  Natalia Mast; Aicha Saadane; Ana Valencia-Olvera; James Constans; Erin Maxfield; Hiroyuki Arakawa; Young Li; Gary Landreth; Irina A Pikuleva
Journal:  Neuropharmacology       Date:  2017-06-24       Impact factor: 5.250

Review 5.  The neurotoxicity of environmental aluminum is still an issue.

Authors:  Stephen C Bondy
Journal:  Neurotoxicology       Date:  2010-05-27       Impact factor: 4.294

Review 6.  Neuropathology of Alzheimer's Disease.

Authors:  Jorge A Trejo-Lopez; Anthony T Yachnis; Stefan Prokop
Journal:  Neurotherapeutics       Date:  2021-11-02       Impact factor: 6.088

7.  Inhaled ultrafine particulate matter affects CNS inflammatory processes and may act via MAP kinase signaling pathways.

Authors:  M T Kleinman; J A Araujo; A Nel; C Sioutas; A Campbell; P Q Cong; H Li; S C Bondy
Journal:  Toxicol Lett       Date:  2008-03-18       Impact factor: 4.372

8.  Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.

Authors:  William E Klunk; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Brian J Lopresti; Scott K Ziolko; Wenzhu Bi; Jessica A Hoge; Ann D Cohen; Milos D Ikonomovic; Judith A Saxton; Beth E Snitz; Daniel A Pollen; Majaz Moonis; Carol F Lippa; Joan M Swearer; Keith A Johnson; Dorene M Rentz; Alan J Fischman; Howard J Aizenstein; Steven T DeKosky
Journal:  J Neurosci       Date:  2007-06-06       Impact factor: 6.167

9.  Altered glycosylation profile of purified plasma ACT from Alzheimer's disease.

Authors:  Manuela Ianni; Marcella Manerba; Giuseppina Di Stefano; Elisa Porcellini; Martina Chiappelli; Ilaria Carbone; Federico Licastro
Journal:  Immun Ageing       Date:  2010-12-16       Impact factor: 6.400

10.  Neuronal death induced by nanomolar amyloid β is mediated by primary phagocytosis of neurons by microglia.

Authors:  Urte Neniskyte; Jonas J Neher; Guy C Brown
Journal:  J Biol Chem       Date:  2011-09-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.